X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DR. REDDYS LAB - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DR. REDDYS LAB LUPIN LTD/
DR. REDDYS LAB
 
P/E (TTM) x 16.8 27.6 60.9% View Chart
P/BV x 3.9 2.8 137.7% View Chart
Dividend Yield % 0.8 1.0 79.0%  

Financials

 LUPIN LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
DR. REDDYS LAB
Mar-16
LUPIN LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,1274,383 48.5%   
Low Rs1,2942,750 47.1%   
Sales per share (Unadj.) Rs304.1920.1 33.0%  
Earnings per share (Unadj.) Rs50.4126.1 40.0%  
Cash flow per share (Unadj.) Rs60.7183.0 33.2%  
Dividends per share (Unadj.) Rs7.5020.00 37.5%  
Dividend yield (eoy) %0.40.6 78.2%  
Book value per share (Unadj.) Rs243.8685.8 35.5%  
Shares outstanding (eoy) m450.58170.61 264.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.63.9 145.1%   
Avg P/E ratio x33.928.3 120.0%  
P/CF ratio (eoy) x28.219.5 144.6%  
Price / Book Value ratio x7.05.2 134.9%  
Dividend payout %14.915.9 93.8%   
Avg Mkt Cap Rs m770,740608,481 126.7%   
No. of employees `00016.421.7 75.5%   
Total wages/salary Rs m21,07731,874 66.1%   
Avg. sales/employee Rs Th8,379.67,244.4 115.7%   
Avg. wages/employee Rs Th1,289.01,470.9 87.6%   
Avg. net profit/employee Rs Th1,388.7992.8 139.9%   
INCOME DATA
Net Sales Rs m137,016156,978 87.3%  
Other income Rs m1,8772,693 69.7%   
Total revenues Rs m138,893159,671 87.0%   
Gross profit Rs m37,53534,587 108.5%  
Depreciation Rs m4,6359,705 47.8%   
Interest Rs m446824 54.2%   
Profit before tax Rs m34,33026,751 128.3%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,5365,237 220.3%   
Profit after tax Rs m22,70721,514 105.5%  
Gross profit margin %27.422.0 124.3%  
Effective tax rate %33.619.6 171.6%   
Net profit margin %16.613.7 120.9%  
BALANCE SHEET DATA
Current assets Rs m97,790118,201 82.7%   
Current liabilities Rs m53,87268,368 78.8%   
Net working cap to sales %32.131.7 101.0%  
Current ratio x1.81.7 105.0%  
Inventory Days Days8560 141.2%  
Debtors Days Days12197 125.1%  
Net fixed assets Rs m86,37972,265 119.5%   
Share capital Rs m901853 105.7%   
"Free" reserves Rs m105,735111,548 94.8%   
Net worth Rs m109,844117,009 93.9%   
Long term debt Rs m53,73910,690 502.7%   
Total assets Rs m224,378200,104 112.1%  
Interest coverage x77.933.5 232.9%   
Debt to equity ratio x0.50.1 535.5%  
Sales to assets ratio x0.60.8 77.8%   
Return on assets %10.311.2 92.4%  
Return on equity %20.718.4 112.4%  
Return on capital %21.221.6 98.2%  
Exports to sales %49.146.3 106.1%   
Imports to sales %7.49.0 83.2%   
Exports (fob) Rs m67,24472,618 92.6%   
Imports (cif) Rs m10,19914,050 72.6%   
Fx inflow Rs m71,40575,405 94.7%   
Fx outflow Rs m17,80727,115 65.7%   
Net fx Rs m53,59848,290 111.0%   
CASH FLOW
From Operations Rs m-3,69040,476 -9.1%  
From Investments Rs m-69,434-19,421 357.5%  
From Financial Activity Rs m58,126-17,009 -341.7%  
Net Cashflow Rs m-14,9984,046 -370.7%  

Share Holding

Indian Promoters % 46.6 25.5 182.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 31.9 35.3 90.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.1 15.3 66.0%  
Shareholders   98,259 75,885 129.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 17, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - SANOFI INDIA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS